Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Lokau, J; Kleinegger, F; Garbers, Y; Waetzig, GH; Grötzinger, J; Rose-John, S; Haybaeck, J; Garbers, C.
Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells.
PLoS One. 2020; 15(5): e0232612-e0232612. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Autor/innen der Med Uni Graz:
Haybäck Johannes
Kleinegger Florian

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Number of Figures: 4
| | | |
Tocilizumab is a humanized monoclonal antibody that is approved for the treatment of different human inflammatory diseases, including rheumatoid arthritis and cytokine release syndrome. Tocilizumab binds to the interleukin-6 receptor (IL-6R) and thereby blocks signaling of the pro-inflammatory cytokine IL-6. Initial studies and all authority assessment reports state that tocilizumab is effective in humans, but cannot bind to the murine or rat IL-6R and thus not block IL-6 signaling in the mouse. However, several recent studies described the use of tocilizumab in mice and reported biological effects that were attributed to IL-6 blockade. In this study, we investigate the capability of tocilizumab to block IL-6 signaling using different human and murine cell lines. Our results unequivocally confirm the original state of the art that tocilizumab blocks signaling via the human IL-6R, but does not block IL-6 signaling in murine cells.

© Med Uni Graz Impressum